ArticleCanadian journal of surgery. Journal canadien de chirurgie
Quality of life following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a Canadian experience.
Article in Canadian journal of surgery. Journal canadien de chirurgie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quality of Life Analysis in SRC + HIPEC Patients: Single-Center Experience.Journal of clinical medicine · 2026Article
- Functional and Participation Outcomes of Colorectal Cancer With Peritoneal Metastasis and Pseudomyxoma Peritonei Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC): A Cross-Sectional Survivorship Study.Advances in rehabilitation science and practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is an effective treatment for select peritoneal surface malignancies, offering a survival benefit. However, the procedure can substantially impact patients' quality of life (QoL) owing to its physiologic and functional effects. We sought to evaluate QoL trajectories over 12 months following CRS/HIPEC and to identify factors influencing outcomes.
methodsA prospective cohort study was performed including patients undergoing CRS/HIPEC between January 2018 and July 2022. Quality of life was assessed preoperatively and at 3, 6, and 12 months postoperatively using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-CR29 questionnaires. Qualitative data from open-ended responses were analyzed thematically.
resultsTwenty-five patients were included in the study. Global health scores declined at 3 months (
conclusionQuality of life after CRS/HIPEC showed dynamic recovery over 12 months and was influenced by clinical, demographic, and psychosocial factors, emphasizing the need for comprehensive perioperative support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.